Top Markets
#1 Audiera Audiera +33.84%
#2 TROLL TROLL +33.46%
#3 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +32.45%
#4 Bitcoin Cash Bitcoin Cash +32.20%
#5 GALA GALA +32.15%
#6 Fabric Protocol Fabric Protocol +31.41%
#7 B3 (Base) B3 (Base) +30.61%
#8 Tutorial Tutorial +28.97%
#9 Kamino Kamino +28.72%
#10 Bless Bless +28.27%
Coin of the day
Audiera Audiera
Settings
Language
ENGLISH
Currency
USD
Theme
Achilles Therapeutics plc Achilles Therapeutics plc

Achilles Therapeutics plc

ACHL
Rank in Stocks #24577
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused... Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.
Share Price
$1.48
Last synced: 2025-03-24
Market Cap
$59.05M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
GB
Trade Achilles Therapeutics plc (ACHL)

Category

Healthcare
P/B ratio for Achilles Therapeutics plc (ACHL)
P/B ratio as of 2026 TTM: 0
According to Achilles Therapeutics plc latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Achilles Therapeutics plc from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH